(Q53521179)
Statements
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) (English)
D Mavroudis
N Malamos
S Kakolyris
I Boukovinas
P Papakotoulas
N Kentepozidis
N Ziras
V Georgoulias
Breast Cancer Investigators of Hellenic Oncology Research Group (HORG), Athens, Greece
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference